Stoke Therapeutics grants 225,000 stock options to CSO
Stoke Therapeutics, Inc. reported that Chief Scientific Officer Thomas McCauley received a grant of stock options covering 225,000 shares of common stock at an exercise price of $29.91 per share, expiring on July 14, 2036.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Stoke Therapeutics, Inc. reported that Chief Scientific Officer Thomas McCauley received a grant of stock options covering 225,000 shares of common stock at an exercise price of $29.91 per share, expiring on July 14, 2036. The option vests as to 1/4 of the award on July 15, 2027, and as to 1/48 of the award monthly thereafter, subject to his continued service.
Insider Trade Summary
Grant/Award: 225,000 shares
Grant/Award
1 txn
Insider
McCauley Thomas
Role
Chief Scientific Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 225,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 225,000 contracts (Direct)
Footnotes (1)
- F1. The stock option vests as to 1/4 of the total award on July 15, 2027, and as to 1/48 of the total award monthly thereafter, subject to the reporting person's continued service to the Issuer on each vesting date.
Key Figures
Options granted: 225,000 shares
Exercise price: $29.91 per share
Underlying shares: 225,000 shares
+3 more
6 metrics
Options granted
225,000 shares
Stock options covering 225,000 shares of common stock granted to Chief Scientific Officer on 2026-07-15
Exercise price
$29.91 per share
Conversion or exercise price of the granted stock options
Underlying shares
225,000 shares
Number of common shares underlying the stock option grant
Post-grant option holdings
225,000 options
Total derivative securities owned directly after the reported grant
Expiration date
2036-07-14
Expiration date of the granted stock option
Initial vesting date
2027-07-15
Date on which 1/4 of the stock option award vests
Key Terms
Stock Option (Right to Buy), exercise price, expiration date, vesting
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 29.9100"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-07-14"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vesting financial
"The stock option vests as to 1/4 of the total award"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Stoke Therapeutics (STOK) report in this Form 4?
Stoke Therapeutics reported that Chief Scientific Officer Thomas McCauley received a grant of stock options for 225,000 shares of common stock at an exercise price of $29.91 per share, with a long-term vesting schedule and expiration on July 14, 2036.
How many stock options were granted to the Stoke Therapeutics (STOK) Chief Scientific Officer?
Chief Scientific Officer Thomas McCauley was granted 225,000 stock options linked to an equal number of common shares. These options are reported as directly owned and represent his total derivative holdings following the reported transaction on July 15, 2026.
What is the exercise price and expiration date of the STOK options granted to Thomas McCauley?
The granted options have an exercise price of $29.91 per share and an expiration date of July 14, 2036. These terms define the price at which he may purchase common shares and the final date on which the options can be exercised.
What is the vesting schedule for the 225,000 Stoke Therapeutics (STOK) stock options?
The option vests as to 1/4 of the total award on July 15, 2027, then as to 1/48 of the total award monthly thereafter. Each vesting installment is conditioned on Thomas McCauley’s continued service to the company on the applicable vesting dates.
Does this Stoke Therapeutics (STOK) Form 4 involve any stock sales or only an option grant?
This Form 4 reflects only an option grant acquisition of 225,000 derivative securities and no reported stock sales. The transaction is coded as a grant or award, increasing Thomas McCauley’s directly held stock option position to 225,000 options.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates